Follow
Arlene Naranjo
Arlene Naranjo
Research Assistant Professor of Biostatistics, University of Florida
Verified email at ufl.edu
Title
Cited by
Cited by
Year
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
TF Eleveld, DA Oldridge, V Bernard, J Koster, LC Daage, SJ Diskin, ...
Nature genetics 47 (8), 864-871, 2015
5352015
Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial
JR Park, SG Kreissman, WB London, A Naranjo, SL Cohn, MD Hogarty, ...
Jama 322 (8), 746-755, 2019
2512019
Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
R Mody, A Naranjo, C Van Ryn, LY Alice, WB London, BL Shulkin, ...
The lancet oncology 18 (7), 946-957, 2017
2382017
Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s oncology group
GA Yanik, MT Parisi, BL Shulkin, A Naranjo, SG Kreissman, WB London, ...
Journal of nuclear medicine 54 (4), 541-548, 2013
2102013
Revised neuroblastoma risk classification system: a report from the Children's Oncology Group
MS Irwin, A Naranjo, FF Zhang, SL Cohn, WB London, JM Gastier-Foster, ...
Journal of Clinical Oncology 39 (29), 3229, 2021
2082021
A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study
JG Nuchtern, WB London, CE Barnewolt, A Naranjo, PW McGrady, ...
Annals of surgery 256 (4), 573-580, 2012
2022012
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study
J Vermeulen, K De Preter, A Naranjo, L Vercruysse, N Van Roy, ...
The lancet oncology 10 (7), 663-671, 2009
1922009
Children's Oncology Group's 2013 blueprint for research: renal tumors
JS Dome, CV Fernandez, EA Mullen, JA Kalapurakal, JI Geller, V Huff, ...
Pediatric blood & cancer 60 (6), 994-1000, 2013
1752013
High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk
EV Barnes, S Narain, A Naranjo, J Shuster, MS Segal, ES Sobel, ...
Lupus 14 (8), 576-582, 2005
1472005
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study
JR Park, JR Scott, CF Stewart, WB London, A Naranjo, VM Santana, ...
Journal of clinical oncology 29 (33), 4351, 2011
1412011
Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children’s Oncology Group study
LL Wang, R Teshiba, N Ikegaki, XX Tang, A Naranjo, WB London, ...
British journal of cancer 113 (1), 57-63, 2015
1322015
Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children’s Oncology Group
R Mody, LY Alice, A Naranjo, FF Zhang, WB London, BL Shulkin, ...
Journal of Clinical Oncology 38 (19), 2160, 2020
1262020
Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group
K Campbell, JM Gastier‐Foster, M Mann, AH Naranjo, C Van Ryn, ...
Cancer 123 (21), 4224-4235, 2017
1252017
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group …
WB London, R Bagatell, BJ Weigel, E Fox, D Guo, C Van Ryn, A Naranjo, ...
Cancer 123 (24), 4914-4923, 2017
1212017
Long-term follow-up of a phase III study of ch14. 18 (dinutuximab)+ cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032
AL Yu, AL Gilman, MF Ozkaynak, A Naranjo, MB Diccianni, J Gan, ...
Clinical Cancer Research 27 (8), 2179-2189, 2021
1202021
Characterization of adolescent and pediatric renal cell carcinoma: a report from the Children's Oncology Group study AREN03B2
JI Geller, PF Ehrlich, NG Cost, G Khanna, EA Mullen, EJ Gratias, ...
Cancer 121 (14), 2457-2464, 2015
1092015
Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG
C Okamatsu, WB London, A Naranjo, MD Hogarty, JM Gastier‐Foster, ...
Pediatric blood & cancer 53 (4), 563-569, 2009
1052009
miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples
K De Preter, P Mestdagh, J Vermeulen, F Zeka, A Naranjo, I Bray, ...
Clinical Cancer Research 17 (24), 7684-7692, 2011
1012011
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's …
JG Villablanca, WB London, A Naranjo, P McGrady, MM Ames, JM Reid, ...
Clinical Cancer Research 17 (21), 6858-6866, 2011
1002011
Pan-neuroblastoma analysis reveals age-and signature-associated driver alterations
SW Brady, Y Liu, X Ma, AM Gout, K Hagiwara, X Zhou, J Wang, M Macias, ...
Nature communications 11 (1), 5183, 2020
952020
The system can't perform the operation now. Try again later.
Articles 1–20